Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
6.56
+0.21 (3.31%)
Mar 10, 2026, 1:46 PM CST
-18.00%
Market Cap 898.72M
Revenue (ttm) 370.00K
Net Income (ttm) -37.78M
Shares Out 137.00M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,002
Average Volume 59,317
Open 6.36
Previous Close 6.35
Day's Range 6.26 - 6.56
52-Week Range 5.25 - 10.20
Beta -0.85
RSI 44.59
Earnings Date Mar 24, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.